Related Experiment Video
Updated: Dec 11, 2025
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
Published on: February 8, 2017
Melanoma brain metastases: review of histopathological features and immune-molecular aspects
Lorenzo Salvati1, Mario Mandalà2, Daniela Massi3
1Department of Experimental & Clinical Medicine, University of Florence, Florence, Italy.
Abstract:
Patients with melanoma brain metastases (MBM) have a dismal prognosis, but the unprecedented advances in systemic therapy alone or in combination with local therapy have now extended the 1-year overall survival rate from 20-25% to nearing 80-85%, mainly in asymptomatic patients. The histopathological and molecular characterization of MBM and the understanding of the microenvironment are critical to more effectively manage patients with advanced melanoma and to design biologically driven clinical trials. This review aims to give an overview of the main histopathological features and the immune-molecular aspects of MBM.
Insights
Melanoma brain metastases survival has dramatically improved with new therapies, nearing 85% 1-year survival. Understanding MBM pathology and microenvironment is key for advanced melanoma patient management.
Area of Science:
- Oncology
- Neurology
- Immunology
Background:
- Melanoma brain metastases (MBM) historically had a poor prognosis.
- Recent advances in systemic and local therapies have significantly improved patient outcomes.
Purpose of the Study:
- To provide an overview of histopathological features of MBM.
- To discuss the immune-molecular aspects of MBM.
- To highlight the importance of MBM characterization for advanced melanoma management.
Main Methods:
- Literature review of recent studies on melanoma brain metastases.
- Analysis of histopathological and molecular data.
- Synthesis of information on MBM microenvironment.
Main Results:
- 1-year overall survival for MBM patients has increased from 20-25% to 80-85%.
- Improvements are most notable in asymptomatic patients.
- Histopathological and molecular characteristics are crucial for treatment strategies.
Conclusions:
- Effective management of advanced melanoma with MBM requires detailed understanding of tumor pathology and microenvironment.
- Biologically driven clinical trials are essential for further progress.
- Current therapeutic advances offer significantly improved survival rates for MBM patients.
